Unknown

Dataset Information

0

Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia.

ABSTRACT: Ibrutinib (Imbruvica): a novel targeted therapy for chronic lymphocytic leukemia.

SUBMITTER: Parmar S 

PROVIDER: S-EPMC4103574 | biostudies-other | 2014 Jul

REPOSITORIES: biostudies-other

Json Xml
altmetric image

Publications

Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia.

Parmar Sapna S   Patel Khilna K   Pinilla-Ibarz Javier J  

P & T : a peer-reviewed journal for formulary management 20140701 7

Ibrutinib (Imbruvica): a novel targeted therapy for chronic lymphocytic leukemia. ...[more]

Similar Datasets

Unknown The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.
| S-EPMC5736707 | biostudies-literature
Unknown Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
| S-EPMC4722809 | biostudies-other
Unknown Ibrutinib (PCI-32765) in chronic lymphocytic leukemia.
| S-EPMC4449150 | biostudies-other
Unknown Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia.
| S-EPMC6966427 | biostudies-literature
Unknown Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia.
| S-EPMC7022232 | biostudies-literature
Unknown Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
| S-EPMC6908306 | biostudies-literature
Genomics miR expression differences in Chronic lymphocytic leukemia patients after ibrutinib therapy
2017-01-25 | GSE84801 | GEO
Unknown Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.
| S-EPMC5296363 | biostudies-literature
Unknown Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
| S-EPMC4520535 | biostudies-literature
Unknown Emergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy.
| S-EPMC7495781 | biostudies-literature